List of trials and treatment arms included in this study.

Trial numbering corresponds to numbering in a comprehensive review of all MRC studies[3], where full references for trial report(s) are listed. Trials conducted in East and Central Africa are listed in Table 1.7, trials conducted in Hong Kong in Table 1.8 and trials conducted in Singapore in Table 1.9 of the review[3].
†This trial was actually of 4 month regimens, but was terminated earlier than planned and patients still on treatment at that time were continued to 6 months of treatment. The results of those on 6 months of treatment were presented in a later publication[44].
*The results of this trial were never published (personal communication, DA Mitchison) and it is therefore not included in the tables of MRC studies in Fox, Ellard and Mitchison[3]. For treatment notation: S  =  Streptomycin, H  =  Isoniazid, T  =  Thiacetazone, Z  =  Pyrazinamide, R  =  Rifampicin, E  =  Ethambutol. Where the regimen has distinct intensive and continuation phases, these are separated by a forward slash with the leading number corresponding to the duration in months. The subscript indicates the number of doses given weekly; the absence of subscript indicates daily dosing. For example, 2SHRE/4SHE2 consists of a 2 month intensive phase of 4 drugs given daily followed by a 4 month continuation phase of 3 drugs each given twice-weekly. The subscript C indicates the drugs were given in a combined formulation. In the fourth Hong Kong study pyrazinamide given once or thrice weekly was added to some of the regimens for the first 2, 4 or 8 weeks. This is indicated by the text in parentheses where, for example, 4wZ1 indicates that once-weekly pyrazinamide was added only for the first 4 weeks.